South Korea Approves First Domestic Radiopharmaceutical for Prostate Cancer Diagnosis

South Korea celebrates a significant milestone in its pharmaceutical industry with the approval of 'ProstaVue Injection' (Florastamine (18F)) as the nation's 43rd domestically developed new drug. This radiopharmaceutical marks a breakthrough in the diagnosis of metastatic prostate cancer, offering a more precise and reliable method compared to existing diagnostic tools.

The development by Futachem, a company already recognized for its work in diagnostic radiopharmaceuticals, underscores South Korea's growing capabilities in advanced medical technology. ProstaVue Injection's ability to accurately identify cancer cells through PET-CT scans is expected to revolutionize the management of prostate cancer, particularly in detecting early-stage metastasis and aiding in more accurate treatment planning. The impressive positive predictive value of approximately 86.96% observed in clinical trials highlights the drug's efficacy.

This achievement is not just a medical advancement but also a testament to South Korea's ambition in the global biopharmaceutical market. Futachem's plans to target not only the domestic market but also international markets like China signify the country's growing influence and competitiveness in specialized medical fields. As the global market for PET-CT prostate cancer diagnostics expands, ProstaVue Injection is poised to become a key revenue driver for Futachem and a source of national pride in medical innovation.

“

We will also lay the groundwork for expanding additional indications and applications. We plan to obtain national approvals by securing additional overseas clinical data. As the market rapidly expands, ProstaVue Injection is expected to become Futachem's core revenue source in the future.